Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer
1997

Study of Doxorubicin and S9788 in Advanced Cancer

Sample size: 38 publication Evidence: moderate

Author Information

Author(s): CJA Punt, EE Voest, E Tueni, AT Van Oosterom, A Back, PHM De Mulder, B Hecquet, C Lucas, B Gerard, H Bleiberg

Primary Institution: University Hospital Nijmegen, The Netherlands

Hypothesis

Can S9788 effectively reverse multidrug resistance in patients with advanced colorectal and renal cell cancer when combined with doxorubicin?

Conclusion

The combination of S9788 and doxorubicin achieved relevant concentrations of S9788 but resulted in significant cardiac arrhythmias, leading to the study's termination.

Supporting Evidence

  • One patient achieved a partial response after previously progressing on doxorubicin alone.
  • Significant increase in WHO grade 3-4 granulocytopenia was observed with the combination treatment.
  • Cardiac arrhythmias were noted in patients receiving the combination treatment.

Takeaway

Doctors tested a new drug called S9788 with another drug, doxorubicin, to help treat cancer, but they found it caused heart problems, so they stopped the study.

Methodology

Patients with advanced colorectal or renal cell cancer were treated with doxorubicin alone or in combination with S9788, and their responses and side effects were monitored.

Potential Biases

Potential bias due to non-randomized treatment assignment and small sample size.

Limitations

The study was terminated early due to safety concerns regarding cardiac arrhythmias.

Participant Demographics

Median age was 61 years, with 27 patients having colorectal cancer and 11 with renal cell cancer.

Statistical Information

P-Value

0.001

Confidence Interval

95% CI 1.9-17% for colorectal cancer response rate

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication